NanoViricides, Inc. NNVC
Set alert
At close · Oct 30
After hours · Oct 30, 7:16 PM ET
- YTD
- +17.70%
- 1 year
- -21.76%
- Open
- 1.41
- Prev close
- 1.43
- Mkt cap
- 33.97M
- Vol
- 224.30K
- Avg vol
- 391.49K
- EPS
- -0.41
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.33
- High
- 1.45
- Forward P/E
- -2.68
- Beta
- 0.97
- Short ratio
- 1.92
- Inst. own
- 9.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 12, 2025
- 50-d avg
- 1.43
- 200-d avg
- 1.66
- 1y target
- 0.00
News
-
1 week ago benzinga.com
NanoViricides Announces That NV-387 Successfully Demonstrated Strong Safety, Tolerability, And Toxicological Parameters In An Animal Model Study Involving Juvenile Mouse Pups
This study is expected to pave the way for pediatric use of NV-387 in clinical trials in children possibly as young as 1 year old. Pediatric drugs for Ebola, Mpox, and Measles, as well as RSV - to…
1 week ago accessnewswire.com
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
The Spreading Ebola Epidemic as well as Mpox Endemic in Africa Disproportionately Impact Children; The Measles Outbreaks Primarily Impact Children SHELTON, CT / ACCESS Newswire / October 20, 2026 /…
-
2 weeks ago benzinga.com
NanoViricides Says Its Phase IIA Ebola Treatment Clinical Trial Of NV-387 Oral Gummies Is Progressing Well
The Phase IIA part of the clinical trial is designed to evaluate different dosage regimens of the oral gummies for the treatment of different severity levels of the Ebola Bundibugyo virus infection…
2 weeks ago accessnewswire.com
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
SHELTON, CT / ACCESS Newswire / October 13, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, said…
3 weeks ago accessnewswire.com
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
SHELTON, CT / ACCESS Newswire / October 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("the Company") is pleased to announce that it will be presenting tomorrow October 7, 2026 at NIBA's 153rd…
-
3 weeks ago benzinga.com
NanoViricides Updates Phase II Trial Of NV-387 Oral Gummies For Ebola Treatment In DRC; Reports Cautious Early Enrollment
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith provides additional details on its Phase II Clinical Trial of…
3 weeks ago accessnewswire.com
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
SHELTON, CT / ACCESS Newswire / October 5, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith…
1 month ago accessnewswire.com
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
SHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June…
-
1 month ago benzinga.com
Nanoviricides Q4 EPS $(0.10), Inline
Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 23.08 percent increase over losses of $(0.13) per share from the same…
1 month ago accessnewswire.com
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape,…
1 month ago accessnewswire.com
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum…
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
-
1 month ago benzinga.com
NanoViricides Announces That Its Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In Democratic Republic Of Congo Is Scheduled To Begin Next Week
Clinical trial is scheduled to start at an Ebola Treatment Center in the Ituri province."NV-387 being an oral drug with broad-spectrum antiviral properties, everyone is rooting for it and hoping that…
1 month ago accessnewswire.com
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape,…
-
1 month ago benzinga.com
NanoViricides Says Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In DR Congo Registered In Pan African Clinical Trials Registry Database
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a…
1 month ago accessnewswire.com
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape,…
-
2 months ago benzinga.com
NanoViricides Advances NV-387 Measles Treatment Toward Phase II Trials Following FDA Rare Pediatric Disease Designation
NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic…
2 months ago accessnewswire.com
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the…
-
2 months ago benzinga.com
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
2 months ago defenseworld.net
NanoViricides (NYSE:NNVC) Trading Down 2.2% – Time to Sell?
NanoViricides, Inc. (NYSE: NNVC - Get Free Report)'s stock price dropped 2.2% during mid-day trading on Thursday. The company traded as low as $1.30 and last traded at $1.31. 203,050 shares changed…
-
2 months ago benzinga.com
NanoViricides Announces Expects Its Phase II Clinical Trial Of NV-387 Oral Gummies To Treat Bundibugyo Ebolavirus And Other Ebola Viruses To Begin Soon In The Democratic Republic Of Congo
Under the leadership of Professor Katoto, NanoViricides, as the drug sponsor of NV-387 Oral Gummies, has received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a…
2 months ago accessnewswire.com
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces…
-
2 months ago benzinga.com
NanoViricides Wins DRC Approval To Begin Phase II Trial Of NV-387 Oral Gummies For Ebola
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received regulatory approval to begin a Phase II…
2 months ago accessnewswire.com
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces…
-
3 months ago benzinga.com
NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus In Democratic Republic Of Congo
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it is eagerly awaiting regulatory approval to begin a…
3 months ago accessnewswire.com
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that…
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's pre-market session. The company's market cap stands at $27.4 million. Akanda (NASDAQ:AKAN) shares…
3 months ago accessnewswire.com
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of…
-
3 months ago benzinga.com
NanoVricides Applies To DRC Regulatory Agency ACOREP For Approval To Begin A Phase II Clinical Trial Of NV-387 Oral Gummies To Treat The Current Bundibugyo Ebolavirus
NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team…
-
3 months ago benzinga.com
NanoViricides Gets National Ethics Committee Approval For Phase II Clinical Study Of NV-387 Oral Gummies To Treat Current Bundibugyo Ebolavirus In Congo
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received National Ethics Committee approval for a…
3 months ago accessnewswire.com
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that…
3 months ago accessnewswire.com
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a…
-
3 months ago benzinga.com
Noble Capital Markets Initiates Coverage On Nanoviricides with Outperform Rating, Announces Price Target of $6
Noble Capital Markets analyst Robert LeBoyer initiates coverage on Nanoviricides (AMEX:NNVC) with a Outperform rating and announces Price Target of $6.
-
3 months ago benzinga.com
NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation As Treatment For Current Bundibugyo Ebolavirus In DRC
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral…
3 months ago accessnewswire.com
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it…
-
4 months ago benzinga.com
FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoViricides' Antiviral Drug NV-387
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic
4 months ago accessnewswire.com
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of…
-
4 months ago benzinga.com
NanoViricides Ships NV-387 Oral Gummies To The Democratic Republic of Congo Ahead Of Patient Enrollment For Its Phase II Clinical Trial Of Monkeypox Treatment
Clinical Trial Site preparations are being performed by our CRO in India, Om Sai Clinical Research Pvt. Ltd., and associates in DRC. The CRO personnel have visited the site several times, despite…
4 months ago accessnewswire.com
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical…
-
4 months ago benzinga.com
NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus Approved By Pillar Committee In Charge In DR Congo
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that its proposal to perform a Phase II…
-
4 months ago benzinga.com
NanoViricides Proposes Phase II Clinical Study Of NV-387 Oral Gummies To Congo To Treat Current Bundibugyo Ebolavirus
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that it has proposed a Phase II…
-
4 months ago benzinga.com
NanoViricides Files Prospectus For Offering $50M Mixed Shelf
https://www.sec.gov/Archives/edgar/data/1379006/000110465926071007/tm2616485d1_s3.htm
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
5 months ago benzinga.com
Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares rose 7% in pre-market trading as Q2 guidance exceeded expectations.
-
5 months ago benzinga.com
NanoViricides Prices Sale Of 1,333,334 Shares And Warrants For Gross Proceeds Of ~$2M
NanoViricides, Inc. (NYSE:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine…
-
6 months ago benzinga.com
NanoViricides' Clinical Stage, Broad-Spectrum, Antiviral Drug NV-387 Granted Orphan Drug Designation By US FDA Office Of Orphan Products Development
NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic…
-
6 months ago benzinga.com
NanoViricides Granted FDA Orphan Drug Designation Status For Treatment Of The Measles Virus
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1140226
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session